Description
LinATAB E 5/25 mg is a combination medication that contains linagliptin and metformin, specifically formulated for the management of type 2 diabetes mellitus. Linagliptin, a DPP-4 inhibitor, works by increasing insulin secretion and decreasing glucagon levels, while metformin enhances insulin sensitivity and reduces glucose production in the liver. This synergistic effect helps to effectively lower blood sugar levels and improve overall glycemic control. The 5/25 mg dosage indicates the specific strengths of each active ingredient, allowing for personalized treatment tailored to individual patient needs. LinATAB E is typically prescribed as part of a comprehensive diabetes management plan that includes lifestyle modifications such as diet and exercise. Patients should adhere to their healthcare provider's instructions to achieve optimal results and minimize the risk of potential side effects.
.webp)
.jpeg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpeg)
.webp)
.jpeg)
.jpg)
.webp)
 400MG.jpg)
.jpg)
 100 IU 3 ML.webp)
.jpg)
.png)
.jpg)
.jpeg)
Change Language